Notice of Intent to issue a Sole Source Award to generate and optimize high-affinity nucleic acid aptamers capable of semi-quantitative detection of TFV-DP and/or TFV for use in both plate-based assays and POC platforms.
The Centers for Disease Control and Prevention (CDC) intends to award a sole source firm-fixed-price contract to the University of North Carolina at Chapel Hill to generate and optimize nucleic acid aptamers for detecting TFV-DP and/or TFV in plate-based and point-of-care platforms. The work will be performed at UNC, which is uniquely qualified due to its co-invention of a related aptamer and established methodologies compatible with CDC’s current efforts. No budget amount is specified. Responses to this notice must be submitted by email to the contract specialist by June 2, 2026. This is not a request for competitive quotes, but all timely responses will be considered.